Hungary's Richter sees shares fly on sales outlook; Amneal nabs 4 Actavis drugs in FTC-ordered sale;

@FiercePharma: MS cases grow by 10% in 5 yrs, with most in US, Europe. Drugs access a problem, esp in low-income countries. More | Follow @FiercePharma

@EricPFierce: The success of some drugs shortly after launch suggests stardom. Special report | Follow @EricPFierce

@CarlyFierce: From today's edition of FierceBiomarkers: Molecular switch could control metastases, aid diagnosis in breast cancer. Article | Follow @CarlyHFierce

> Hungary's Gedeon Richter saw shares surge as an analyst issued an optimistic outlook for sales of the company's two core drugs. Report

> Amneal Pharmaceuticals agreed to buy four of the products Actavis ($ACT) must sell to win Federal Trade Commission (FTC) approval of its Warner Chilcott ($WCRX) buyout. Report

> Pfizer ($PFE) tapped Adobe Systems CEO Shantanu Narayen to join its board. Report

> The FDA banned three arsenic drugs used in poultry and pig feeds; the makers of the drugs, Zoetis ($ZTS) and Fleming Labs, had already largely withdrawn them from the market. Report (sub. req.)

> India's Sun Pharmaceuticals and U.S.-based Intrexon ($XON) are teaming up to develop eye drugs. Report

> Amgen ($AMGN) wrapped up its $9.7 billion buyout of Onyx Pharmaceuticals ($ONXX) with 78% of Onyx shares tendered. Report

Medical Device News

@FierceMedDev: ICYMI yesterday... Report: Blackstone, Bain, other equity firms bid for J&J's Ortho Clinical Diagnostics unit. Article | Follow @FierceMedDev

@MarkHFierce: Myriad's stock dived earlier this week over Dx reimbursement fears driven by what turned out to be a clerical error. Story from FierceDiagnostics | Follow @MarkHFierce

> Quest unloads colon cancer Dx business as revamp marches on. Report

> Given Imaging should climb onto the auction block, investor says. News

> Street sneers at Stryker's $1.7B Mako deal, but CEO stays upbeat. Story

> GE will test imaging agent on MS patients taking Biogen's Tysabri. More

Biotech News

@FierceBiotech: ICYMI yesterday: What happens to the FDA in a government shutdown? Story | Follow @FierceBiotech

@JohnCFierce: Cancer immunotherapies turn a corner in race to megablockbuster market. Article | Follow @JohnCFierce

@EmilyMFierce: ICYMI yesterday: Government shutdown halts NIH research, CDC disease surveillance. Story from FierceBiotech Research | Follow @EmilyMFierce

@DamianFierce: Wall Street is less than thrilled with Stryker's $1.7B deal for MAKO, but CEO says just you wait. Story from FierceMedicalDevices | Follow @DamianFierce

> Fate IPO flop raises fresh concerns about investors' appetite for biotech. News

> VC Frazier Healthcare nails $377M fund with eye on biotech startups. More

Biomarkers News

> Report: Biomarkers market to grow 18.5% by 2018. Story

> Medicare's rejection of Alzheimer's test leaves Lilly in the lurch. Article

> Quintiles looks to biomarkers to speed up cancer trials. Report

> Research finds possible biomarker for Parkinson's with mild cognitive impairment. News

Drug Delivery News

@MichaelGFierce: Vaginal polymer ring delivers long-term HIV-preventing drug. Item | Follow @MichaelGFierce

> Hypertension drug could help chemo infiltrate tumors. More

> John Theurer Cancer Center touts two oral lymphoma drug studies. Story

> Oral peptide delivery biz Enteris lands Nordic partnership. Report

> MIT nanoparticles help deliver vaccines to mucosal surfaces. More

> Medtronic lands U.S. approval of early-generation artificial pancreas. Article

Diagnostics News

> Singulex will jump into in vitro diagnostics backed by $55M in debt, equity. Item

> UCLA team develops superfast fluorescent camera with Dx benefit. Story

> MA company debuts Dx device that could dramatically speed up HIV, other tests. Report

> Chronix preclinical study boosts CLIA goal for cell-free DNA cancer test. More

> Myriad reimbursement scare sent stock on roller coaster ride. Article

> Roche, Pacific Biosciences forge clinical Dx deal. Story

And Finally... Scientists said exercise may be as effective as drugs in treating heart disease and recommended that clinical trials for new drugs in the field use exercise as a comparator. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.